Article

Jessica Ryan Discusses Recovery from an Extreme Oncoplasty

Author(s):

Jessica Ryan

Breast surgeon Jessica Ryan discusses recovery from an extreme oncoplasty.

Jessica Ryan, breast surgeon, Elliot Breast Health Center, Manchester, New Hampshire, discusses recovery from an extreme oncoplasty.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.
Expert Offers Surveillance, Lifestyle Guidance After CRC, Anal Cancer
Image of Dr. D'sa
Understanding the Evolution of Waldenström Macroglobulinemia Treatment
Image of doctor.
Early Arterial Thrombosis May Signal Future Cancer Risk
Image of Dr. Deville.
What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer?
Image of man.
Understanding Unique Treatment Options Across Bladder Cancer Care
Image of kelly.
Preparing For Survivorship After Lymphoma Treatment in AYA PatientsPreparing For Survivorship After Lymphoma Treatment in AYA Patients
Robotic and minimally invasive kidney cancer surgery may reduce pain, shorten recovery time and preserve kidney function, according to Dr. Armine Smith.
Robotic Kidney Cancer Surgery May Aid Recovery, Spare Kidney Function
Image of Doctor.
Long-Term Prostate Cancer Data Highlights Risk and Survivorship Needs
Building long-term trust with providers can help patients with MPNs feel supported, encourage them to speak up and navigate care with confidence.
Why Relationships are Key When Caring For Patients With MPNs
The field of radiation oncology has advanced in brain cancer treatment with precise therapeutic approaches including proton and carbon therapy.
Advances in Radiation Improve Precision in Brain Cancer Therapy
Related Content
Itovebi plus Ibrance and Faslodex improved overall survival in patients with HR+, HER2– breast cancer versus placebo: © stock.adobe.com.
May 22nd 2025

Itovebi Triplet Combo Boosts Survival in HR+, HER2– Breast Cancer

Caroline Seymour
Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Image of blood cells.
May 21st 2025

FDA’s ODAC Casts Votes on the Use of Certain Treatment Options in Cancer Care

Ryan Scott
The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma patient populations, respectively.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of two woman with pink ribbon.
May 16th 2025

Samuraciclib Therapy Combo Shows Responses in HR+ Advanced Breast Cancer

Ryan Scott
Recent phase 2 data support combination treatment with samuraciclib for those with HR+ advanced breast cancer following prior CDK4/6 inhibitor therapy.
Breast.
May 13th 2025

Understanding the Unique Task of Treating Older Patients With Breast Cancer

Ryan Scott
Dr. Hyman B. Muss discusses the unique challenges that older patients with breast cancer face during and after treatment for their disease.